parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.00 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including microglia; strongest in retinal horizontal cells	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 16034

RASSF8 in dopamine neurons, braak+0.46 (p 0.212) → +0.30 (p 0.428)receipt 16042
RASSF8 in microglia, braak-0.25 (p 0.524) → +0.11 (p 0.775)receipt 16041

receipt 16042: RASSF8 in dopamine neurons, braak

power: full sample +0.41 (p 0.091, n 18), 95% CI -0.07 to +0.74. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.32 (p 0.191, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.39 (p 0.111, n 18). could be the mix.
skeptic: leave-one-out range +0.35 to +0.49, sign flips 0; without severely affected donors +0.41 (p 0.091, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RASSF8 in dopamine neurons.

case closed: nothing better to follow up.

receipt 16041: RASSF8 in microglia, braak

power: full sample +0.00 (p 0.997, n 18), 95% CI -0.47 to +0.47. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.01 (p 0.976, n 18). does not hold up.
composition: microglia share of nuclei vs axis -0.11 (p 0.652); controlling for it: -0.01 (p 0.976, n 18). could be the mix.
skeptic: leave-one-out range -0.13 to +0.12, sign flips 9; without severely affected donors +0.00 (p 0.997, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for RASSF8 in microglia.

case closed: nothing better to follow up.

loading the receipts